Integrated Investment Consultants LLC Raises Stake in Amgen Inc. (NASDAQ:AMGN)

Integrated Investment Consultants LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 97.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,826 shares of the medical research company’s stock after purchasing an additional 1,395 shares during the period. Integrated Investment Consultants LLC’s holdings in Amgen were worth $911,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. CANADA LIFE ASSURANCE Co raised its stake in Amgen by 2.7% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 49,931 shares of the medical research company’s stock valued at $14,241,000 after purchasing an additional 1,311 shares during the last quarter. Gamco Investors INC. ET AL raised its stake in Amgen by 5.3% in the 1st quarter. Gamco Investors INC. ET AL now owns 5,431 shares of the medical research company’s stock valued at $1,544,000 after purchasing an additional 271 shares during the last quarter. Lazard Asset Management LLC increased its stake in shares of Amgen by 4.4% during the 1st quarter. Lazard Asset Management LLC now owns 31,841 shares of the medical research company’s stock valued at $9,051,000 after acquiring an additional 1,353 shares during the last quarter. Steel Grove Capital Advisors LLC increased its stake in shares of Amgen by 30.5% during the 1st quarter. Steel Grove Capital Advisors LLC now owns 1,283 shares of the medical research company’s stock valued at $365,000 after acquiring an additional 300 shares during the last quarter. Finally, Kestra Advisory Services LLC increased its stake in shares of Amgen by 25.6% during the 1st quarter. Kestra Advisory Services LLC now owns 80,582 shares of the medical research company’s stock valued at $22,911,000 after acquiring an additional 16,407 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on AMGN shares. Barclays boosted their target price on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Citigroup started coverage on Amgen in a report on Thursday, November 14th. They set a “neutral” rating and a $335.00 target price for the company. Jefferies Financial Group reiterated a “buy” rating and set a $380.00 target price on shares of Amgen in a report on Tuesday, November 12th. Oppenheimer reiterated an “outperform” rating and set a $380.00 target price on shares of Amgen in a report on Wednesday, August 7th. Finally, Robert W. Baird reiterated an “underperform” rating and set a $215.00 target price on shares of Amgen in a report on Wednesday, September 25th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Amgen has an average rating of “Moderate Buy” and a consensus target price of $333.57.

Amgen Trading Up 0.7 %

NASDAQ:AMGN opened at $289.77 on Friday. The stock has a fifty day simple moving average of $317.28 and a 200 day simple moving average of $318.02. The firm has a market capitalization of $155.76 billion, a price-to-earnings ratio of 37.10, a price-to-earnings-growth ratio of 2.50 and a beta of 0.60. Amgen Inc. has a 1-year low of $260.68 and a 1-year high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. Amgen’s revenue was up 23.2% on a year-over-year basis. During the same quarter last year, the business posted $4.96 EPS. Sell-side analysts forecast that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be given a dividend of $2.25 per share. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a yield of 3.11%. Amgen’s payout ratio is presently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.